Page last updated: 2024-12-07
16-dehydroprogesterone
## 16-Dehydroprogesterone: A key player in steroid hormone research
**16-Dehydroprogesterone (16-DHP)** is a naturally occurring steroid hormone with a unique structure. It's a derivative of progesterone, but with a double bond at the C16 position. This seemingly small change has significant implications for its biological activity and its role in research.
**Here's what makes 16-DHP important for research:**
**1. Potential therapeutic applications:**
* **Anti-inflammatory and immunomodulatory effects:** Studies suggest that 16-DHP may have anti-inflammatory properties, potentially useful for treating autoimmune disorders and inflammatory conditions. Its ability to modulate immune responses also makes it an intriguing target for research in areas like transplantation and allergy.
* **Anti-cancer activity:** Preclinical research indicates that 16-DHP might exhibit anti-cancer activity, particularly against certain types of breast cancer and leukemia. Its mechanism of action is still under investigation, but it appears to interfere with cell growth and proliferation.
* **Neuroprotective effects:** 16-DHP has shown promise in protecting neurons from damage, potentially leading to treatments for neurodegenerative diseases like Alzheimer's and Parkinson's.
**2. Understanding steroid hormone metabolism:**
* **Metabolic pathway insights:** 16-DHP is an intermediate in the metabolic pathway of progesterone, making it crucial for studying the synthesis and breakdown of this important hormone. Understanding the conversion of progesterone to 16-DHP can provide valuable information about the regulation of hormone levels and potential therapeutic targets.
* **Exploring structural modifications:** Comparing the effects of 16-DHP with other progesterone derivatives allows researchers to pinpoint the specific functional groups responsible for its unique biological activity. This knowledge can help design novel, more potent and targeted therapeutic agents.
**3. Studying the role of steroid hormones in various biological processes:**
* **Reproductive health:** 16-DHP's influence on the reproductive system, particularly the menstrual cycle, is being actively investigated. Its role in fertility and other reproductive functions is a key area of research.
* **Hormonal regulation:** 16-DHP interacts with various steroid hormone receptors, influencing their activation and downstream signaling pathways. This makes it essential for understanding how steroid hormones regulate a wide range of bodily functions.
**Ongoing research:**
* **Developing novel drug candidates:** The potential therapeutic benefits of 16-DHP are driving research into its pharmacokinetic properties, identifying optimal dosage forms, and developing safe and effective drugs based on this molecule.
* **Exploring its mechanism of action:** Researchers are actively investigating the molecular targets and signaling pathways involved in the biological effects of 16-DHP. This information is crucial for understanding its therapeutic potential and developing targeted treatments.
* **Clinical trials:** Some early clinical trials are underway to assess the safety and efficacy of 16-DHP in treating specific diseases, such as certain cancers and inflammatory conditions.
**Overall, 16-dehydroprogesterone remains a fascinating area of study with significant implications for understanding steroid hormone metabolism, developing new therapeutic strategies, and improving human health.**
Cross-References
ID Source | ID |
PubMed CID | 101964 |
CHEBI ID | 18204 |
SCHEMBL ID | 4661581 |
MeSH ID | M0090778 |
Synonyms (41)
Synonym |
pregna-4,16-diene-3,20-dione |
delta(4,16)-pregnadiene-3,20-dione |
CHEBI:18204 |
3,20-dioxopregna-4,16-diene |
pregna-4,20-dione |
nsc-9785 |
nsc-11037 |
nsc9785 |
nsc11037 |
.delta.16-progesterone |
3,16-diene |
nsc 11037 |
.delta.4,20-dione |
1096-38-4 |
C03207 |
16-dehydroprogesterone |
16,17-didehydroprogesterone |
16-dehydroprogesterone, 97% |
LMST02030163 |
(8r,9s,10r,13s,14s)-17-acetyl-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15-decahydrocyclopenta[a]phenanthren-3-one |
delta4,16-pregnadiene-3,20-dione |
ju0yq9dz2o , |
einecs 214-142-8 |
nsc 9785 |
unii-ju0yq9dz2o |
S6140 |
4,16-pregnadiene-3,20-dione |
AKOS022172049 |
SCHEMBL4661581 |
.delta.4,16-pregnadiene-3,20-dione |
delta.16-progesterone |
d4,16-pregnadiene-3,20-dione |
d16-progesterone |
DS-6807 |
DTXSID10862535 |
Q27102899 |
CS-0099261 |
HY-128378 |
16-?dehydroprogesterone |
16-ehydroprogesterone |
PD124055 |
Drug Classes (3)
Class | Description |
20-oxo steroid | An oxo steroid carrying an oxo group at position 20. |
3-oxo-Delta(4) steroid | A 3-oxo steroid conjugated to a C=C double bond at the alpha,beta position. |
enone | An alpha,beta-unsaturated ketone of general formula R(1)R(2)C=CR(3)-C(=O)R(4) (R(4) =/= H) in which the C=O function is conjugated to a C=C double bond at the alpha,beta position. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (8)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 4 (50.00) | 18.7374 |
1990's | 2 (25.00) | 18.2507 |
2000's | 1 (12.50) | 29.6817 |
2010's | 1 (12.50) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.13
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 12.13 (24.57) | Research Supply Index | 2.20 (2.92) | Research Growth Index | 4.32 (4.65) | Search Engine Demand Index | 0.00 (26.88) | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 1 (12.50%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (87.50%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |